COMPARE · Data as of August 12, 2026
AUPH vs GENB
Verdict: Side-by-side breakdown using the Bull Rankings model. AUPH scored 76.2, GENB scored 25.7 — AUPH leads.
Compare another set
AUPH
Aurinia Pharmaceuticals Inc.
76.2
$15.45 · $2.1B
fundamentals as of
Score gap
50.5
AUPH leads
GENB
Generate Biomedicines, Inc.
25.7
$15.09 · $1.9B
fundamentals as of
The model, pillar by pillar (0–100 each)
AUPH
stronger →← stronger
GENB
74
Qualityreturns · margins · balance sheet
34
67
Growthrevenue & earnings expansion
100
90
Valuevaluation vs sector peers
2
AUPH is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
AUPH
GENB
$175mC
FCF
-$246mF
+20.4%A-
Rev
+55.9%A
0.10B+
D/E
0.14B+
6.7xA
P/E
—
0.33A
PEG
—
—
P/S
73.1xD
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
AUPH
GENB
15% below
Price vs fair valuelower is cheaper
—
~4%/yr
Growth the price implies10-yr FCF · lower = less priced in
—
+4%
1-yr DCF upside
—
+18%
5-yr DCF upside
—
+40%
10-yr DCF upside
—
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
AUPH
Why this score
- Earnings outpace cash
GENB
Why this score
- Short track record
The companies
AUPHAurinia Pharmaceuticals Inc.
Why now
Biotechnology · market cap $2.1b. 20% off the 52-week high of $19.25. Revenue growing +20%, comfortably above the S&P median. PEG 0.33 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $17.00 (implying +10% upside).
Moat
ROE 51% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Beta 1.40 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
GENBGenerate Biomedicines, Inc.
Why now
Biotechnology · market cap $1.9b. 17% off the 52-week high of $18.18. Revenue growing +56% — in hypergrowth territory. 5 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $25.60 (implying +70% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$246m) — capital raises or debt issuance likely required; dilution / leverage risk. P/S 73.1x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where AUPH and GENB diverge
On the headline score the gap is 50.5 points in favour of AUPH. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueAUPH 90.5 · GENB 2.3AUPH +88.2
- QualityAUPH 73.6 · GENB 33.9AUPH +39.7
- GrowthAUPH 66.5 · GENB 100.0GENB +33.5
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.